CSCGlobal Capital Markets (Singapore) Pte. Ltd., acting as security agent, has released the encumbrance on 3,41,48,000 equity shares of Cohance Lifesciences Limited on September 18, 2025. This release is a result of Jusmiral Holdings Limited (a promoter) selling shares on the open market, reducing its stake from 33.08% to 24.15%. The move is related to a Notes Purchase Agreement.
Shareholding Adjustment
The Security Agent, CSCGlobal Capital Markets (Singapore) Pte. Ltd., has announced the release of encumbrance on a portion of Cohance Lifesciences Limited’s shares. This adjustment follows a transaction by Jusmiral Holdings Limited, a promoter of Cohance Lifesciences.
Details of the Transaction
Jusmiral Holdings Limited sold 3,41,48,000 equity shares (8.93% of total shares) on September 18, 2025, through an on-market sale. This sale resulted in a reduction of Jusmiral Holdings Limited’s stake in Cohance Lifesciences. The shareholding has been reduced from 12,65,38,578 shares (33.08%) to 9,23,90,578 shares (24.15%).
Impact on Encumbrance
As a consequence of this sale, the number of shares encumbered by CSCGlobal Capital Markets (Singapore) Pte. Ltd. as the Security Agent, acting on behalf of secured parties in relation to term note facilities made available, has been adjusted. Berhyanda Shares remain at 12,75,39,592, or 33.34% while Jusmiral Shares have changed to 9,23,90,578 representing 24.15%
Related Agreement
This transaction is related to the Notes Purchase Agreement dated May 29, 2024, involving Jusmiral Holdings Limited, Jusmiral Midco Limited (“Jusmiral Parent”), CSCGlobal Capital Markets (Singapore) Pte. Ltd., and other finance parties. Under this agreement, certain restrictions and requirements apply to the shares held by Jusmiral Holdings Limited.
Source: BSE